PMID- 22451257
OWN - NLM
STAT- MEDLINE
DCOM- 20121231
LR  - 20131121
IS  - 1573-9686 (Electronic)
IS  - 0090-6964 (Linking)
VI  - 40
IP  - 9
DP  - 2012 Sep
TI  - The development of novel biodegradable bifurcation stents for the sustainable 
      release of anti-proliferative sirolimus.
PG  - 1961-70
LID - 10.1007/s10439-012-0556-x [doi]
AB  - In this report, a balloon-expandable, biodegradable, drug-eluting bifurcation 
      stent (DEBS) that provides a sustainable release of anti-proliferative sirolimus 
      was developed. Biodegradable bifurcation stents, made of polycaprolactone, were 
      first manufactured by injection molding and hot spot welding techniques. Various 
      properties of the fabricated stents, including compression strengths, collapse 
      pressures, and flow pattern in a circulation test, were characterized. The 
      experimental results showed that biodegradable bifurcation stents exhibited 
      comparable mechanical properties with those of metallic stents and superior flow 
      behavior to that of metallic bifurcation stents deployed via the T And small 
      Protrusion approach. Polylactide-polyglycolide (PLGA) copolymer and sirolimus 
      were then dissolved in acetonitrile and coated onto the surface of the stents by 
      a spray coating device. An elution method and a high performance liquid 
      chromatography analysis were utilized to examine the in vitro release 
      characteristics of sirolimus. Biodegradable bifurcation stents released high 
      concentrations of sirolimus for more than 6 weeks, and the total period of drug 
      release could be prolonged by increasing the drug loading of the PLGA/sirolimus 
      coating layers. In addition, the eluted drug could effectively inhibit the 
      proliferation of smooth muscle cells. The developed DEBS in this study may 
      provide a promising strategy for the treatment of cardiovascular bifurcation 
      lesions.
FAU - Lee, Cheng-Hung
AU  - Lee CH
AD  - Second Section of Cardiology, Department of Internal Medicine, Chang Gung 
      Memorial Hospital, Linkou, Taiwan.
FAU - Chen, Chia-Jung
AU  - Chen CJ
FAU - Liu, Shih-Jung
AU  - Liu SJ
FAU - Hsiao, Chao-Ying
AU  - Hsiao CY
FAU - Chen, Jan-Kan
AU  - Chen JK
LA  - eng
PT  - Journal Article
DEP - 20120327
PL  - United States
TA  - Ann Biomed Eng
JT  - Annals of biomedical engineering
JID - 0361512
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Delayed-Action Preparations)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/*administration & dosage
MH  - Aorta, Thoracic/cytology
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Delayed-Action Preparations
MH  - Drug Delivery Systems
MH  - *Drug-Eluting Stents
MH  - Myocytes, Smooth Muscle/cytology/drug effects
MH  - Rats
MH  - Sirolimus/*administration & dosage
EDAT- 2012/03/28 06:00
MHDA- 2013/01/01 06:00
CRDT- 2012/03/28 06:00
PHST- 2012/01/07 00:00 [received]
PHST- 2012/03/21 00:00 [accepted]
PHST- 2012/03/28 06:00 [entrez]
PHST- 2012/03/28 06:00 [pubmed]
PHST- 2013/01/01 06:00 [medline]
AID - 10.1007/s10439-012-0556-x [doi]
PST - ppublish
SO  - Ann Biomed Eng. 2012 Sep;40(9):1961-70. doi: 10.1007/s10439-012-0556-x. Epub 2012 
      Mar 27.